{"id":77,"date":"2023-11-30T13:33:33","date_gmt":"2023-11-30T13:33:33","guid":{"rendered":"https:\/\/presonc.w.uib.no\/?page_id=77"},"modified":"2023-12-02T10:10:14","modified_gmt":"2023-12-02T10:10:14","slug":"myklebost-group-publications-2012-23","status":"publish","type":"page","link":"https:\/\/presonc.w.uib.no\/en\/myklebost-group-publications-2012-23\/","title":{"rendered":"Myklebost Lab Publications 2012-23"},"content":{"rendered":"
    \n
  1. Naml\u00f8s H, Kresse SH, M\u00fcller CR, Henriksen J<\/strong>, S\u00e6ter G, Bruland \u00d8, Holdhus R, Bjerkehagen B, Steen VM , Myklebost O<\/strong> (2012<\/strong>) Global gene expression profiling of human osteosarcomas reveals metastasis-associated chemokine pattern Sarcoma<\/strong> 2012, 1\u201312. doi:10.1155\/2012\/639038<\/li>\n
  2. Thomas DM, Wilhelm M, Cleton-Jansen AM, Dirksen U, Entz-Werl\u00e9 N, Gelderblom H, Hassan B, J\u00fcrgens H, Koster J, Kovar H, Lankester AC, Lewis IJ, Myklebost O<\/strong>, Nathrath MHM, Picci P, Whelan JS, Hogendoorn PCW, Bielack SS (2012<\/strong>) Workshop report on the European Bone Sarcoma Networking Meeting: integration of clinical trials with tumor biology Journal of Adolescent and Young Adult Oncology<\/strong>Vol 1 DOI: 10.1089\/jayao.2012.0005<\/li>\n
  3. KuijjerML, Rydbeck H<\/strong>, Kresse SH<\/strong>, Buddingh EP, B\u00fcrger H, Myklebost O<\/strong>, Hogendoorn PCW, Meza-Zepeda LA<\/strong>, Cleton-Jansen AM (2012<\/strong>) Identification of osteosarcoma driver genes by integrative analysis of copy number and gene expression data Genes Chromosomes Cancer <\/strong>51:696-706<\/li>\n
  4. Stratford EW, Castro R, Daffinrud J, Sk\u00e5rn M, Lauvrak SU, Munthe E, Myklebost O <\/strong>(2012<\/strong>) Characterization of liposarcoma cell lines for preclinical and biological studies Sarcoma <\/strong>2012 doi:10.1155\/2012\/148614<\/li>\n
  5. Ohnstad HO, Castro R, Sun J, <\/strong>Heintz KM, Vassilev LT, Bjerkehagen B, Kresse SH, Meza- Zepeda LA, Myklebost O<\/strong> (2012)\u00a0<\/strong>Correlation of TP53 and MDM2 genotypes with response to therapy in sarcoma.Cancer<\/strong>DOI:\u00a010.1002\/cncr.27837<\/li>\n
  6. Naml\u00f8s HM, Meza-Zepeda LA, Bar\u00f8y T, \u00d8stensen IHG, Kresse SH<\/strong>, Kuijjer ML, Serra M, B\u00fcrger H, <\/strong>Cleton-Jansen AM, Myklebost O (2012) <\/strong>Modulation of the Osteosarcoma Expression Phenotype by MicroRNAs. PLoS One<\/strong> DOI: 10.1371\/journal.pone.0048262<\/li>\n
  7. Kresse SH, Rydbeck H, Sk\u00e5rn M, Naml\u00f8s HM, Barragan-Polania AH, <\/strong>Cleton-Jansen AM, Serra M, Liest\u00f8l K, Hogendoorn PCW, Hovig, E, Myklebost; O, Meza-Zepeda LA (2012) <\/strong>Integrative Analysis Reveals Relationships of Genetic and Epigenetic Alterations in Osteosarcoma. PLoS One<\/strong> DOI: 10.1371\/journal.pone.0048262<\/li>\n
  8. Doorn J, Hugo Fernandes H, Lee B, van de Peppel J, van Leeuwen JPTM, De Vries MR, Aref Z, Quax PHA, Myklebost O<\/strong>, Saris D, van Blitterswijk CA, de Boer J. (2013<\/strong>) A small molecule approach to engineering vascularized tissue. Biomaterials<\/strong> 34:3053-63. doi: 10.1016\/j.biomaterials.2012.12.037 IF8<\/em><\/li>\n
  9. Bianchini L, Birtwisle L, Sa\u00e2da E, Bazin A, Long E, Roussel JF, Michiels JF, Forest F, Dani C, Myklebost O<\/strong>, Birtwisle-Peyrottes I, Pedeutour F. (2013<\/strong>) Identification of PPAP2B as a novel recurrent translocation partner gene of HMGA2 in lipomas. Genes Chromosomes Cancer<\/strong> doi: 10.1002\/gcc.22055<\/li>\n
  10. Stratford EW, Bostad M, Castro R, Skarpend E, Berg K, H\u00f8gset A, Myklebost O, Selbo PK (2013<\/strong>) Photochemical internalization of CD133-targeting immunotoxins efficiently depletes sarcoma cells with stem-like properties and reduces tumorigenicity Biochim Biophys Acta<\/strong> 1830:4235\u20134243 doi:10.1016\/j.bbagen.2013.04.033<\/a><\/li>\n
  11. Kuijjer ML, Peterse EFP, van den Akker BEWM, Briaire-de Bruijn IH, Serra M, Meza-Zepeda LA, Myklebost O<\/strong>, Hassan AB, Hogendoorn PCW, Cleton-Jansen AM (2013<\/strong>) IR\/IGF1R signaling as potential target for treatment of high-grade osteosarcoma BMC Cancer<\/strong> 13<\/strong>:245\u00a0doi:10.1186\/1471-2407-13-245<\/li>\n
  12. Sandberg CJ, Altschuler G, Jeong J, Str\u00f8mme KK, Stangeland B, Murrell W, Grasmo-Wendler UH, Myklebost O<\/strong>, Helseth E, Vik-Mo EO, Hide W, Langmoen IA (2013) Comparison of glioma stem cells to neural stem cells from the adult human brain identifies dysregulated Wnt- signaling and a fingerprint associated with clinical outcome Experimental Cell Research<\/strong>, doi 10.1016\/j.yexcr.2013.06.004<\/li>\n
  13. Nome T, Thomassen GOS, Bakken AC, Bruun J, Ahlquist T, Lorenz S, Sun J,<\/strong> Barros-Silva JD, Myklebost O<\/strong>, Teixeira M, Meza-Zepeda LA<\/strong>, Lothe RA, Skotheim RI (2013) Common fusion transcripts identified in colorectal cancer cell lines by high throughput RNA sequencing. Translational Oncology<\/strong> 6:546-53<\/li>\n
  14. Lauvrak SU, Munthe E, Kresse SH, Stratford EW, Naml\u00f8s HM, Meza-Zepeda LA Myklebost O<\/strong>(2013<\/strong>) Functional characterization of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes\u00a0Br. J. Cancer<\/strong> 109:2228-36<\/li>\n
  15. Sk\u00e5rn M, Bar\u00f8y T, Stratford EW, Myklebost O (2013)<\/strong> Epigenetic regulation and functional characterization of mir-142 in mesenchymal cells PLoS One<\/strong> 8: e79231. doi:10.1371\/journal.pone.0079231<\/a><\/li>\n
  16. Behjati S, Tarpey PS, Presneau N, Pillay N, Van Loo P, Wedge DC, Cooke SL, Gudem G, Davies H, Nik-Zainal S, Gamble J, Hardy C, Latimer C, Maddison M,Martin S,McLaren S, Mudie L, O\u2019Meara S, Robinson B, Butler A, Teague JW, Kathri B, Halai D, Myklebost O<\/strong>, Baumhoer D, Jundt G, Tirabosco R, Amary F, Futreal PA, Stratton MR, Campbell PJ, Flanagan AM (2013) <\/strong>Distinct H3F3A and H3F3B driver variants define chondroblastoma and giant cell tumour of bone Nat Genet<\/em><\/strong> 45:1479-82. doi: 10.1038\/ng.2814<\/a><\/li>\n
  17. Stratford EW, Daffinrud J, Munthe E, Castro R<\/strong>, Waaler J, Krauss S, Myklebost O<\/strong> (2013<\/strong>) The tankyrase-specific inhibitor JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines. Cancer Medicine<\/strong> 3:36-46 doi: 10.1002\/cam4.170<\/a><\/li>\n
  18. Chilamakuri CSR, Lorenz S<\/strong>, Madoui MA, Vod\u00e1k DA, Sun J, Hovig W, Myklebost O<\/strong>, Meza-Zepeda LA (2014<\/strong>) Performance Comparison of four exome capturing systems for deep sequencing BMC Genomics <\/strong>15:449 doi:10.1186\/1471-2164-15-449<\/em><\/li>\n
  19. 123<\/strong>. Bar\u00f8y T<\/strong>, Kresse SH<\/strong>, Sk\u00e5rn M<\/strong>, Stabell M<\/strong>, Castro R<\/strong>, Lauvrak S<\/strong>, Hopmeier D<\/strong>, Llombart-Bosch A, Myklebost O<\/strong>, Meza-Zepeda LA (2014<\/strong>) Reexpression of LSAMP inhibits tumor growth in a preclinical osteosarcoma model. Molecular Cancer <\/strong>13:93, doi:<\/em>1186\/1476-4598-13-93<\/em><\/a><\/li>\n<\/ol>\n

    124\u00a0\u00a0\u00a0\u00a0 H\u00e5kelien AM, Bryne JC, Harstad KG, Lorenz S, <\/strong>Paulsen J, Sun J, <\/strong>Mikkelsen TS, Myklebost O, Meza Zepeda LA (2014) <\/strong>The regulatory landscape of osteogenic differentiation. Stem Cells<\/strong> 32:2780-93DOI:\u00a010.1002\/stem.1759<\/em><\/p>\n

    125<\/strong>\u00a0\u00a0\u00a0\u00a0 Sk\u00e5rn M, Noordhuis P,<\/strong> Wang MY, Veuger MJT, Kresse SH, Egeland EV,<\/strong> Micci F, Naml\u00f8s HM, H\u00e5kelien AM, Olafsrud SM, Lorenz S, <\/strong>Haraldsen G, Kvalheim G, Meza-Zepeda LA, Myklebost O <\/strong>(2014<\/strong>) Generation and characterisation of an immortalised human bone marrow derived mesenchymal stromal cell line. Stem Cells and Development<\/strong> doi:10.1089\/scd.2013.0599<\/em><\/p>\n

    126\u00a0\u00a0\u00a0\u00a0 <\/strong>Anninga JK, Cleton-Jansen AM, Hassan B, Amary MF, Baumhoer D, Blay JY, Brugieres L, Ferrari S, J\u00fcrgens H, Kempf-Bielack B, Kovar H, Myklebost O<\/strong>, Nathrath M, Picci P, Riegman P, Schilham MW, Soliman R, Stark DP, Strauss A, Sydes M, Tarpey P, Thomas D, Whelan J, Wilhelm M, Zamzam M, Gelderblom H, Bielack SS (2014<\/strong>) Workshop Report on the 2nd Joint ENCCA\/EuroSARC European Bone Sarcoma Network Meeting: Integration of Clinical Trials with Tumour Biology. Clinical Sarcoma Research<\/strong>4:4, doi:10.1186\/2045-3329-4-4<\/em><\/p>\n

    127\u00a0\u00a0\u00a0\u00a0 Stratford EW, Myklebost O <\/strong>(2014<\/strong>) TRAP1 is a novel interaction partner of PML, localised with PML in nuclear bodies and relocating with PML to the cytoplasm following stress Annual research and review in biology<\/strong> 4:3026-36<\/p>\n

      \n
    1. 128<\/strong>. Wennerstr\u00f6m AB<\/strong>, Lothe IMB, Sandhu V, Kure E, Myklebost O, Munthe E<\/strong> (2014<\/strong>) Generation and characterisation of novel pancreatic adenocarcinoma xenograft models and corresponding primary cell lines. PLoS One<\/strong> 9:e103873<\/li>\n
    2. Tubio JMC, Li Y, Ju YS, Martincorena I, Cooke SL, Tojo M, Gundem G, Pipinikas CP, Zamora J, Raine K, Menzies A, Roman-Garcia P, Gerstung M, Shlien A, Tarpey PS, Papaemmanuil E, Knappskog S, Van Loo P, Ramakrishna M, Davies HR, Marshall J, Wedge DC, Teague JW, Butler AP, Nik-Zainal S, Alexandrov L, Behjati S, Yates LR, Bolli N, Mudie L, Hardy C, Martin S, McLaren S, O\u2019Meara S, Andreson E, Maddison M, Gamble S, ICGC Breast Cancer Group, ICGC Bone Cancer Group<\/strong>, ICGC Prostate Cancer Group, Foster C, Warren AY, Whitaker H, Brewer D, Eeles R, Cooper C, Neal D, Lynch AG, Visakorpi T, Isaacs WB, van’t Veer L, Caldas C, Desmedt C, Sotiriou C, Aparicio A, Foekens JA, Eyfj\u00f6rd JE, Lakhani SR, Thomas G, Myklebost O<\/strong>, Span PN, B\u00f8rresen-Dale AL, Richardson AL,van de Vijver M, Vincent-Salomon A, van den Eynden GG, Flanagan AM, Futreal PA, Janes SM, Bova GS, Stratton MR, McDermott U, Campbell PJ (2014<\/strong>) Extensive transduction of non-repetitive DNA mediated by L1 retrotransposition in cancer genomes Science<\/strong> Vol. 345 no. 6196:1251343 DOI: 10.1126\/science.1251343<\/li>\n
    3. Garsed DW, Marshall OJ, Corbin VDA, Hsu A, di Stefano L, Schr\u00f6der J, Li J, Feng ZP, Kim BW, Kowarsky M, Lansdell B, Brookwell R, Myklebost O, Meza-Zepeda LA, <\/strong>Holloway AJ, Pedeutour F, Choo KHA, Damore MA, Deans AJ, Papenfuss AT, Thomas DM (2014) <\/strong>Architecture and Evolution of a Cancer Neochromosome, Cancer Cell <\/strong>26:653-667<\/li>\n
    4. Serguienko A, Grad I, Wennerstr\u00f8m AB, Meza-Zepeda LA,<\/strong> Thiede B, Stratford EW, Ola Myklebost O, Munthe E<\/strong> (2015<\/strong>) Metabolic reprogramming of metastatic breast cancer and melanoma by let-7a microRNA Oncotarget<\/strong> 6: 2451-2465<\/li>\n
    5. Naderi EH, Ugland H, Myklebost O<\/strong>, Sandnes DL, Torgersen ML, Josefsen D, Ellen Ruud E, Naderi S, Blomhoff HK (2015<\/strong>) Bone marrow stroma-derived PGE2<\/sub> protects BCP-ALL cells from DNA damage-induced p53 accumulation and cell death, Mol Cancer<\/strong> in press <\/em>doi:10.1186\/s12943-014-0278-9<\/li>\n<\/ol>\n

      133<\/strong>\u00a0\u00a0\u00a0\u00a0 Rustad EH, Dai HY, Hov H, Coward E, Beisvag V, Myklebost, Ola<\/strong>, Nakken S, Vodak D, Meza-Zepeda LA<\/strong>, Hovig E, Sandvik A, Wader KF, Misund K, Sundan A, Aarset H, Waage A (2015<\/strong>) Clinical and biological implications of BRAF V600E mutation in multiple myeloma. Blood Cancer J<\/strong>doi:10.1038\/bcj.2015.24<\/p>\n

      134\u00a0\u00a0\u00a0\u00a0 <\/strong>Safavi S, J\u00e4rnum S, Vannas C, Udane S, Jonasson E, Tomic TT, Grundevik P, Fagman H, Hansson M, Kalender Z, Jauhiainen A, Dolatabadi S, Stratford EW, Myklebost O<\/strong>, Eriksson M, Stock ES, St\u00e5hlberg A, \u00c5man P (2015<\/strong>) HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid\/round cell liposarcoma and causes massive cell death in vitro and in vivo. Oncotarget<\/strong> DOI: 10.18632\/oncotarget.6336<\/p>\n

      135<\/strong>\u00a0\u00a0\u00a0\u00a0 Ju YS, Tubio JMC, Mifsud W, Fu B, Davies HR, Ramakrishna M, Li Y, Yates L, Gundem G, Tarpey PS, Behjati S, Papaemmanuil E, Martin S, Fullam A,Gerstung M, ICGC Prostate Cancer Working Group, ICGC Bone Cancer Working Group, ICGC Breast Cancer Working Group, Nangalia J, Green AR, Caldas C, Borg \u00c5, Tutt A, Ta M, Lee M, van\u2019t Veer LJ, Tan BKT, Aparicio S, Span PN, Martens JWM, Knappskog S, Vincent-Salomon A, B\u00f8rresen-Dale AL, Eyfjo\u0308rd JE, Myklebost O<\/strong>,\u00a0 Flanagan AM, Foster C, Neal DE, Cooper C, Eeles R, Lakhani SR, Desmedt C, Thomas G, Richardson AL, Purdie CA, Thompson AM, McDermott U, Yang F, Nik-Zainal S, Campbell PM, Stratton MR (2015<\/strong>) Frequent somatic transfer of mitochondrial DNA into the nuclear genome of human cancer cells Genome Res<\/strong> 25:814-24. doi: 10.1101\/gr.190470.115.<\/p>\n

      136<\/strong>\u00a0\u00a0\u00a0\u00a0 Kanojia D, Nagata Y, Garg M, Lee DH, Anand MT, Christoph H, Klein HU, Said JW, Doan NB, Mohith S, Gunasekar S, Myklebost O<\/strong>, Yang H, Dugas M, Meza-Zepeda LA<\/strong>, Silberman AW, Forscher C, Ogawa S, Koeffler HP (2015<\/strong>) Genomic landscape of liposarcoma Oncotarget <\/strong>DOI: 10.18632\/oncotarget.6464<\/p>\n

      137\u00a0\u00a0\u00a0\u00a0 <\/strong>Lorenz S, Bar\u00f8y T, Sun J, <\/strong>Nome T, Vod\u00e1k D, Bryne JC, H\u00e5kelien AM, <\/strong>Fernandez-Cuesta L, M\u00f6hlendick B, Rieder H, Szuhai K, Zaikova O, Ahlquist TC, Thomassen GOS, Skotheim RI, Lothe RA, Tarpey P, Campbell P, Flanagan A, Meza-Zepeda LA, Myklebost O (2015) <\/strong>Unscrambling the genomic chaos of osteosarcoma reveals recurrent rearrangements and frequent novel TP53 aberrations Oncotarget <\/strong>DOI: 10.18632\/oncotarget.6567<\/p>\n

      138 \u00a0\u00a0\u00a0 <\/strong>Halvorsen AR, Silwal-Pandit L, Meza-Zepeda LA<\/strong>, Vodak D, Vu P, Sagerup C, Hovig E, Myklebost O<\/strong>; B\u00f8rresen-Dale AL, Brustugun OT, Helland \u00c5 (2016<\/strong>) TP53 mutation spectrum in smokers and never smoking lung cancer patients Frontiers in Genetics<\/strong> 7:85.<\/p>\n

      139\u00a0\u00a0\u00a0\u00a0 <\/strong>Ballinger ML, Goode DL, Ray-Coquard I, James PA, Mitchell G, Niedermayr E, Puri A, Schiffman JD, Dite GS, Cipponi A, Maki RG, Brohl AS, Myklebost O, Stratford EW, Lorenz S<\/strong>, Ahn SM, Ahn JH, Kim JE, Shanley S, Beshay V, Randall L, Judson I, Seddon B, Cambell IG, Young MA, Sarin R, Blay JY, O’Donoghue SI, Thomas D (2016<\/strong>)\u00a0Novel monogenic and polygenic determinants of sarcoma risk: an international study of 1162 families Lancet Oncology<\/strong> 17:1261\u20131271, Editorial comment: \u201dAre sarcomas hereditary?\u201d<\/p>\n

        \n
      1. Hanes R, Grad I, Lorenz S, Stratford EW, Munthe E, Reddy CCS, Meza-Zepeda LA, Myklebost O<\/strong>(2016<\/strong>). Amplified FRS2 identified as a target for treatment of dedifferentiated liposarcoma by genome sequencing and functional validation. Oncotarget<\/strong> 7:54583.<\/li>\n
      2. 141<\/strong>. Sandhu V, Wedge DC, Lothe IMB, Labori KJ, Dentro SC, Buanes T, Skrede ML, Dalsgaard AM,Munthe E, Myklebost O<\/strong>, Lingj\u00e6rde OC, B\u00f8rressen-Dale AL, Ikdahl T, Van Loo P, Nord S (2016) The genomic landscape of pancreatic and periampullary adenocarcinoma. Cancer Research<\/strong> 76(17):1-11<\/li>\n
      3. 142<\/strong>. Kager L, Whelan J, Dirksen U, Hassan B, Anninga J, Bennister L, Bov\u00e9e JV, Brennan B, Broto JM, Brugi\u00e8res L, Cleton-Jansen AM, Copland C, Dutour A, Fagioli F, Ferrari S, Fiocco M, Fleuren E, Gaspar N, Gelderblom H, Gerrand C, Ger\u00df J, Gonzato O, van der Graaf W, Hecker-Nolting S, Herrero-Mart\u00edn D, Klco-Brosius S, Kovar H, Ladenstein R, Lancia C, LeDeley MC, McCabe MG, Metzler M, Myklebost O<\/strong>, Nathrath M, Picci P, Potratz J, Redini F, Richter GH, Reinke D, Rutkowski P, Scotlandi K, Strauss S, Thomas D, Tirado OM, Tirode F, Vassal G, Bielack SS (2016<\/strong>) The ENCCA-WP7 \/ EuroSarc \/ EEC \/ PROVABES \/ EURAMOS 3rd European Bone Sarcoma Networking Meeting\/Joint Workshop of EU Bone Sarcoma Translational Research Networks; Vienna, Austria, September 24-25, 2015. Workshop Report. Clin Sarcoma Res<\/strong>. 16;6:3<\/li>\n<\/ol>\n

        143\u00a0\u00a0\u00a0\u00a0 Bar\u00f8y T, Chilamakuri CSR, Lorenz S, Sun J, <\/strong>Bruland \u00d8S, Myklebost O, Meza-Zepeda LA<\/strong> (2016<\/strong>) Genome analysis of osteosarcoma progression samples identifies FGFR1 overexpression as a potential treatment target and CHM as a candidate tumor suppressor gene Plos One<\/strong> 11: e0163859 doi: 10.1371\/journal.pone.0163859<\/p>\n

        144\u00a0\u00a0\u00a0\u00a0 Naml\u00f8s HM<\/strong>, Zaikova O, Bjerkehagen B, Vod\u00e1k D, Hovig E, Myklebost O<\/strong>, Boye K, Meza-Zepeda LA <\/strong>(2016<\/strong>) Use of liquid biopsies to monitor disease progression in a sarcoma patient: a case report BMC Cancer<\/strong> 17:29 doi: 10.1186\/s12885-016-2992-8<\/p>\n

        145\u00a0\u00a0\u00a0\u00a0 <\/strong>Helland \u00c5, Brustugun OT, Nakken S, Halvorsen AR, D\u00f8nnem T, Bremnes R, Busund LT, Sun J, Lorenz S<\/strong>, Solberg SK, J\u00f8rgensen LH, Vodak D, Myklebost O<\/strong>, Hovig E, Meza-Zepeda LA<\/strong> (2017<\/strong>) High number of kinome-mutations in non-small cell lung cancer is associated with reduced immune response and poor relapse-free survival. Int J Cancer<\/strong> 141:184-190 doi: 10.1002\/ijc.30726<\/p>\n

        146\u00a0\u00a0\u00a0\u00a0 <\/strong>Rustad EH, Coward E, Skyt\u00f8en ER, Misund K, Holien T, Standal T, B\u00f8rset M, Beisvag V, Myklebost O, Meza-Zepeda LA<\/strong>, Dai HY, Sundan A, Waage A (2017<\/strong>) Monitoring of Multiple Myeloma by quantification of recurrent mutations in serum Haematologica<\/strong> 102:1266-1272 doi: 10.3324\/haematol.2016.160564<\/p>\n

        147<\/strong>\u00a0\u00a0\u00a0\u00a0 Behjati S, Tarpey PS, Haase K, Ye H, Young MD, Alexandrov LB, Farndon SJ, Collord G, Wedge DC, Martincorena I, Cooke SL, Davies H, Mifsud W, Lidgren M, Martin S, Latimer C, Maddison M, Butler AP, Teague JW, Pillay N, Shlien A, McDermott U, Futreal PA, Baumhoer D, Zaikova O, Bjerkehagen B, Myklebost O<\/strong>, Amary MF, Tirabosco R, Van Loo P, Stratton MR, Flanagan AM, Campbell PJ (2017<\/strong>) Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma Nature Communications <\/strong>23:15936 doi: 10.1038\/ncomms15936<\/p>\n

        148\u00a0\u00a0\u00a0\u00a0 <\/strong>Sveen A, Johannessen B, Tengs T, Danielsen SA, Eilertsen IA, Lind GE, Berg KCG, Leithe E, Meza-Zepeda LA<\/strong>, Domingo E, Myklebost O<\/strong>, Kerr D, Tomlinson I, Nesbakken A, Skotheim RI, Lothe RA (2017<\/strong>) Multilevel genomics of colorectal cancers with microsatellite instability \u2013 clinical impact of JAK1 mutations and consensus molecular subtype 1 Genome Medicine<\/strong> 9:46 doi: 10.1186\/s13073-017-0434-0<\/p>\n

        149<\/strong>\u00a0\u00a0\u00a0\u00a0 Berg KCG, Eide PW, Eilertsen IA, Johannessen B, Bruun J, Danielsen SA, Bj\u00f8rnslett M, Meza-Zepeda LA<\/strong>, Ekn\u00e6s M, Lind GE, Myklebost O<\/strong>, Skotheim RI, Sveen A, Lothe RA (2017<\/strong>) Multi-omics of 34 colorectal cancer cell lines – a resource for biomedical studies Mol Cancer<\/strong> 16:116 doi: 10.1186\/s12943-017-0691-y<\/p>\n

        150\u00a0\u00a0\u00a0\u00a0 Engkvist ME, Stratford EW, Lorenz S, Meza-Zepeda LA, Munthe E<\/strong>, Myklebost O<\/strong> (2017<\/strong>) Analysis of the miR-34 family functions in breast cancer reveals annotation error of miR-34b Sci Rep<\/strong>doi:10.1038\/s41598-017-10189-1<\/p>\n

        151\u00a0\u00a0\u00a0\u00a0 Serguienko A, Hanes R, Grad I, Wang MY, Munthe E,\u00a0 Myklebost O (2017) <\/strong>PP2A regulatory subunit B55\u03b3 is a gatekeeper of osteoblast maturation and lineage maintenance Stem Cells Devel <\/strong>26: 1375-1383 doi: 10.1089\/scd.2017.0129<\/p>\n

        152\u00a0\u00a0\u00a0\u00a0 <\/strong>Nakken S, Fournous G, Vodak D, Aasheim B, Myklebost O<\/strong>, Hovig E (2017<\/strong>) Personal Cancer Genome Reporter: Variant Interpretation Report For Precision Oncology. Bioinformatics <\/strong>1\u20133 doi: 10.1093\/bioinformatics\/btx817<\/p>\n

        153\u00a0\u00a0\u00a0\u00a0 Kresse SK, Naml\u00f8s HM, Lorenz S, <\/strong>Berner JM, Ola Myklebost O, <\/strong>Bjerkehagen B, Meza-Zepeda LA (2018) <\/strong>Evaluation of commercial DNA and RNA extraction methods for high-throughput sequencing of FFPE samples. PLoS One <\/strong>https:\/\/doi.org\/10.1371\/journal.pone.0197456<\/a><\/p>\n

        154\u00a0\u00a0\u00a0\u00a0 <\/strong>Voda\u0301k D, Lorenz S<\/strong>, Nakken S, Aasheim LB, Holte H, Bai B, Myklebost O<\/strong>, Meza-Zepeda LA<\/strong>, Hovig E (2018) Sample-Index Misassignment Impacts Tumour Exome Sequencing Sci. Rep.<\/strong> DOI:10.1038\/s41598-018-23563-4<\/a><\/p>\n

        155<\/strong>\u00a0\u00a0\u00a0\u00a0 Gouravan S, Meza-Zepeda LA, Myklebost O, Stratford EW, Munthe E<\/strong> (2018<\/strong>) Preclinical evaluation of vemurafenib as therapy for BRAFV600E mutated sarcomas Int J Mol Sci<\/strong>doi:10.3390\/ijms19040969<\/a><\/p>\n

        156\u00a0\u00a0\u00a0\u00a0 Naml\u00f8s H, Boye K<\/strong>, Mishkin SJ, Bar\u00f8y T, Lorenz S<\/strong>, Bjerkehagen B, Stratford EW, Munthe E<\/strong>, Kudlow BA, Myklebost O, Meza-Zepeda LA<\/strong> (2018<\/strong>) Non-invasive detection of ctDNA reveals intratumour heterogeneity and is significantly associated with aggressive GIST Mol Cancer Ther <\/strong>doi: 10.1158\/1535-7163.MCT-18-0174<\/p>\n

        157\u00a0\u00a0\u00a0\u00a0 <\/strong>Birkeland E, Zhang S, Poduval D, Geisler J, Nakken S, Vodak D, Meza-Zepeda LA<\/strong>, Hovig E, Myklebost O,<\/strong> Knappskog S, L\u00f8nning PE (2018<\/strong>) Patterns of genomic evolution in advanced melanoma. Nature Comm<\/u><\/em> <\/strong>DOI:10.1038\/s41467-018-05063-1<\/p>\n

        158\u00a0\u00a0\u00a0\u00a0 Serguienko A<\/strong>, Wang MY, Myklebost O<\/strong> (2018<\/strong>) Real-time vital mineralization detection and quantification during in vitro osteoblast differentiation. Biological Procedures Online<\/strong>, ,\u00a0DOI:10.1186\/s12575-018-0079-4<\/p>\n

        159\u00a0\u00a0\u00a0\u00a0 <\/strong>L\u00f8vf M, Zhao S, Axcrona U, Johannesen B, Bakken AC, Carm KT, Hoff AH, Myklebost O, Meza-Zepeda LA<\/strong>, Lie AK, Axcrona K, Lothe RA, Skotheim RI (2018<\/strong>) High degree of genomic heterogeneity in multifocal primary prostate cancer Eur Urology<\/strong><\/u><\/em> in press<\/em> JIF 17,6<\/p>\n

        160\u00a0\u00a0\u00a0\u00a0 <\/strong>Strauss SJ, Anninga J, Baglio B, Baumhoer D, Behjati S, Bielack S, Boye K, Broto JM, Cleton\u2011Jansen AM, Degasperi A, Evans A, Fagioli F, Fiocco M, Gaspar N, Heymann D, Hindi N, Lancia C, Myklebost O, <\/strong>Nathrath M, Redini F, Scotlandi K, Tirtei E, Vanden Eynden M, Whelan J (2018<\/strong>) Report from the 4th European Bone Sarcoma Networking meeting: focus on osteosarcoma Clin Sarcoma Res 8:17 <\/strong>\u00a0https:\/\/doi.org\/10.1186\/s13569-018-0103-0<\/a><\/p>\n

        161<\/strong>\u00a0\u00a0\u00a0\u00a0 Hanes R, Munthe E, Grad I<\/strong>, Han J, Karlsen I,\u00a0McCormack E, Meza-Zepeda LA, Stratford EW, Myklebost\u00a0O (2019)<\/strong> Preclinical evaluation of the pan-FGFR inhibitor LY2874455 in\u00a0FRS2-amplified liposarcoma. Cells<\/strong> 8:189<\/p>\n

        162<\/strong>\u00a0\u00a0\u00a0\u00a0 Serguienko A<\/strong>, Braadland P, Meza-Zepeda LA<\/strong>, Bjerkehagen B, Myklebost O<\/strong> (2020<\/strong>) Accurate 3-gene-signature for early diagnosis of liposarcoma progression. Clinical Sarcoma Research<\/strong>\u00a010:4 DOI: 10.1186\/s13569-020-0126-1<\/p>\n

        163\u00a0\u00a0\u00a0\u00a0 <\/strong>The ICGC\/TCGA Pan-Cancer Analysis of Whole Genomes Consortium [Incl\u00a0Bjerkehagen B,<\/strong>Myklebost O, Zaikova O<\/strong>] (2020<\/strong>) Pan-cancer analysis of whole genomes. Nature<\/u><\/em><\/strong> 578:82\u201393 doi:10.1038\/s41586-020-1969-6<\/p>\n

        164\u00a0\u00a0\u00a0\u00a0 <\/strong>Wise JF, Nakken S, Steen CB, Vod\u00e1k D, Tr\u00f8en G, Johannessen B, Lingj\u00e6rde OC, Hilden V, Blaker YN, Bai B, Aasheim LB, Pasanen A, Lorenz S, Sveen A, Lothe RA, Myklebost O<\/strong>, Lepp\u00e4 S, Meza-Zepeda LA<\/strong>, Beiske K, Lawrence MS, Hovig E, Myklebust JH, Smeland EB, Holte H (2020<\/strong>) Mutational Dynamics and Immune Evasion in Diffuse Large B-cell Lymphoma: A Call for Relapse Sampling Blood Adv <\/strong>12;4:1859-1866. doi: 10.1182\/bloodadvances.2019001325.<\/p>\n

        165\u00a0\u00a0\u00a0\u00a0 <\/strong>Li CH, Prokopec SD, Sun R, Yousif F, Schmitz N, PCAWG Tumour Subtypes and Clinical Translation, Boutros PC, PCAWG Consortium (Including Bjerkehagen B, Myklebost O, Zaikova O<\/strong>) (2020<\/strong>) Sex differences in oncogenic mutational processes. Nature Communications<\/u><\/em><\/strong> 11:4330 DOI: 10.1038\/s41467-020-17359-2<\/p>\n

        166\u00a0\u00a0\u00a0\u00a0 <\/strong>Bailey MH, Meyerson WU, Dursi LJ,\u00a0 \u2026.., Gerstein MB, Ding L & PCAWG Consortium [including Bjerkehagen B, Myklebost O, Zaikova O<\/strong>] (2020<\/strong>) Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples Nature Communications<\/u><\/em><\/strong> volume 11, Article number: 4748<\/p>\n

        167\u00a0\u00a0\u00a0\u00a0 <\/strong>D\u00f6rnen J, Myklebost O<\/strong>, Dittmar (2020<\/strong>) Cell Fusion of Mesenchymal Stem\/Stromal Cells and Breast Cancer Cells leads to the Formation of Hybrid Cells exhibiting diverse and individual (stem cell) Characteristics. International Journal of Molecular Sciences<\/strong> doi: 10.3390\/ijms21249636<\/p>\n

        168\u00a0\u00a0\u00a0\u00a0 <\/strong>Cort\u00e9s-Ciriano I, Lee JJ, Xi R, Jain D, Jung YL, Yang L, Gordenin D, Klimczak LJ, Zhang CZ, Pellman DS; PCAWG Structural Variation Working Group; Park PJ; PCAWG Consortium [Including Zaikova O, Bjerkehagen B,<\/strong> Myklebost O<\/strong>] (2020<\/strong>) Comprehensive analysis of chromothripsis in 2,658 human cancers using whole-genome sequencing. Nat Genet.<\/u><\/em><\/strong> 52:331-341. doi: 10.1038\/s41588-019-0576-7<\/p>\n

        169\u00a0\u00a0\u00a0\u00a0 <\/strong>Akdemir KC, Le VT, Chandran S, Li Y, Verhaak RG, Beroukhim R, Campbell PJ, Chin L, Dixon JR, Futreal PA; PCAWG Structural Variation Working Group; PCAWG Consortium [Including Zaikova O, Bjerkehagen B,<\/strong> Myklebost O<\/strong>] (2020<\/strong>) Disruption of chromatin folding domains by somatic genomic rearrangements in human cancer. Nat Genet.<\/u><\/em><\/strong> 52:294-305. doi: 10.1038\/s41588-019-0564-y<\/p>\n

        170\u00a0\u00a0\u00a0\u00a0 <\/strong>Rodriguez-Martin B, Alvarez EG, Baez-Ortega A, Zamora J, Supek F, \u2026, PCAWG Structural Variation Working Group; Campbell PJ, Tubio JMC; PCAWG Consortium [Including Zaikova O, Bjerkehagen B,<\/strong>Myklebost O<\/strong>] (2020<\/strong>) Pan-cancer analysis of whole genomes identifies driver rearrangements promoted by LINE-1 retrotransposition. Nat Genet.<\/u><\/em><\/strong> 52:306-319. doi: 10.1038\/s41588-019-0562-0<\/p>\n

        171\u00a0\u00a0\u00a0\u00a0 <\/strong>Yuan Y, Ju YS, Kim Y, Li J, Wang Y, Yoon CJ, Yang Y, Martincorena I, Creighton CJ, Weinstein JN, Xu Y, Han L, Kim HL, Nakagawa H, Park K, Campbell PJ, Liang H; PCAWG Consortium [Including Zaikova O, Bjerkehagen B,<\/strong> Myklebost O<\/strong>] (2020<\/strong>) Comprehensive molecular characterization of mitochondrial genomes in human cancers. Nat Genet.<\/u><\/em><\/strong> 52:342-352. doi: 10.1038\/s41588-019-0557-x<\/p>\n

        172<\/strong>\u00a0\u00a0\u00a0\u00a0 Yakneen S, Waszak SM; PCAWG Technical Working Group; Gertz M, Korbel JO; PCAWG Consortium [Including Zaikova O, Bjerkehagen B,<\/strong> Myklebost O<\/strong>] (2020<\/strong>) Butler enables rapid cloud-based analysis of thousands of human genomes. Nat Biotechnol.<\/u><\/em><\/strong> 38:288-292. doi: 10.1038\/s41587-019-0360-3<\/p>\n

        173\u00a0\u00a0\u00a0\u00a0 <\/strong>Carlevaro-Fita J, Lanz\u00f3s A, Feuerbach L, Hong C, Mas-Ponte D, Pedersen JS; PCAWG Drivers and Functional Interpretation Group; Johnson R; PCAWG Consortium [Including Zaikova O, Bjerkehagen B,<\/strong>Myklebost O<\/strong>] (2020<\/strong>) Cancer LncRNA Census reveals evidence for deep functional conservation of long noncoding RNAs in tumorigenesis. Commun Biol<\/em><\/strong>. 3:56. doi: 10.1038\/s42003-019-0741-7<\/p>\n

        174\u00a0\u00a0\u00a0\u00a0 <\/strong>Reyna MA, Haan D, Paczkowska M, Verbeke LPC, Vazquez M, Kahraman A, Pulido-Tamayo S, Barenboim J, Wadi L, Dhingra P, Shrestha R, Getz G, Lawrence MS, Pedersen JS, Rubin MA, Wheeler DA, Brunak S, Izarzugaza JMG, Khurana E, Marchal K, von Mering C, Sahinalp SC, Valencia A; PCAWG Drivers and Functional Interpretation Working Group; Reimand J, Stuart JM, Raphael BJ; PCAWG Consortium [Including Zaikova O, Bjerkehagen B,<\/strong> Myklebost O<\/strong>] (2020<\/strong>) Pathway and network analysis of more than 2500 whole cancer genomes. Nat Commun.<\/u><\/em><\/strong> 11:729. doi: 10.1038\/s41467-020-14367-0<\/p>\n

        175\u00a0\u00a0\u00a0\u00a0 <\/strong>Jiao W, Atwal G, Polak P, Karlic R, Cuppen E; PCAWG Tumor Subtypes and Clinical Translation Working Group; Danyi A, de Ridder J, van Herpen C, Lolkema MP, Steeghs N, Getz G, Morris QD, Stein LD; PCAWG Consortium [Including Zaikova O, Bjerkehagen B,<\/strong> Myklebost O<\/strong>] (2020<\/strong>) A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns. Nat Commun.<\/u><\/em><\/strong>11:728. doi: 10.1038\/s41467-019-13825-8<\/p>\n

        176\u00a0\u00a0\u00a0\u00a0 <\/strong>Paczkowska M, Barenboim J, Sintupisut N, Fox NS, Zhu H, Abd-Rabbo D, Mee MW, Boutros PC; PCAWG Drivers and Functional Interpretation Working Group; Reimand J; PCAWG Consortium [Including Zaikova O, Bjerkehagen B,<\/strong> Myklebost O<\/strong>] (2020<\/strong>) Integrative pathway enrichment analysis of multivariate omics data. Nat Commun<\/u><\/em><\/strong>. 11:735. doi: 10.1038\/s41467-019-13983-9<\/p>\n

        177\u00a0\u00a0\u00a0\u00a0 <\/strong>Cmero M, Yuan K, Ong CS, Schr\u00f6der J; PCAWG Evolution and Heterogeneity Working Group; Corcoran NM, Papenfuss T, Hovens CM, Markowetz F, Macintyre G; PCAWG Consortium [Including Zaikova O, Bjerkehagen B,<\/strong> Myklebost O<\/strong>] (2020<\/strong>) Inferring structural variant cancer cell fraction. Nat Commun<\/u><\/em><\/strong>. 11:730. doi: 10.1038\/s41467-020-14351-8<\/p>\n

        178\u00a0\u00a0\u00a0\u00a0 <\/strong>Rubanova Y, Shi R, Harrigan CF, Li R, Wintersinger J, Sahin N, Deshwar AG; PCAWG Evolution and Heterogeneity Working Group; Morris QD; PCAWG Consortium [Including Zaikova O, Bjerkehagen B,<\/strong>Myklebost O<\/strong>] (2020<\/strong>) Reconstructing evolutionary trajectories of mutation signature activities in cancer using TrackSig. Nat Commun.<\/u><\/em><\/strong> 11:731. doi: 10.1038\/s41467-020-14352-7<\/p>\n

        179\u00a0\u00a0\u00a0\u00a0 <\/strong>Zhang Y, Chen F, Fonseca NA, He Y, Fujita M, Nakagawa H, Zhang Z, Brazma A; PCAWG Transcriptome Working Group; PCAWG Structural Variation Working Group; Creighton CJ; PCAWG Consortium [Including Zaikova O, Bjerkehagen B,<\/strong> Myklebost O<\/strong>] (2020<\/strong>) High-coverage whole-genome analysis of 1220 cancers reveals hundreds of genes deregulated by rearrangement-mediated cis-regulatory alterations. Nat Commun.<\/u><\/em><\/strong> 11:736. doi: 10.1038\/s41467-019-13885-w<\/p>\n

        180\u00a0\u00a0\u00a0\u00a0 <\/strong>Bhandari V, Li CH, Bristow RG, Boutros PC; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O<\/strong>] (2020<\/strong>) Divergent mutational processes distinguish hypoxic and normoxic tumours. Nat Commun.<\/u><\/em><\/strong> 11:737. doi: 10.1038\/s41467-019-14052-x<\/p>\n

        181\u00a0\u00a0\u00a0\u00a0 <\/strong>Shuai S; PCAWG Drivers and Functional Interpretation Working Group; Gallinger S, Stein LD; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O<\/strong>] (2020<\/strong>) Combined burden and functional impact tests for cancer driver discovery using DriverPower. Nat Commun.<\/u><\/em><\/strong> 11:734. doi: 10.1038\/s41467-019-13929-1<\/p>\n

        182\u00a0\u00a0\u00a0\u00a0 <\/strong>Sieverling L, Hong C, Koser SD, Ginsbach P, Kleinheinz K, Hutter B, Braun DM, Cort\u00e9s-Ciriano I, Xi R, Kabbe R, Park PJ, Eils R, Schlesner M; PCAWG-Structural Variation Working Group; Brors B, Rippe K, Jones DTW, Feuerbach L; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O<\/strong>] (2020<\/strong>) Genomic footprints of activated telomere maintenance mechanisms in cancer. Nat Commun.<\/u><\/em><\/strong> 11:733. doi: 10.1038\/s41467-019-13824-9<\/p>\n

        183\u00a0\u00a0\u00a0\u00a0 <\/strong>PCAWG Transcriptome Core Group; Calabrese C, Davidson NR, Demircio\u011flu D, Fonseca NA, He Y, Kahles A, Lehmann KV, Liu F, Shiraishi Y, Soulette CM, Urban L, Greger L, Li S, Liu D, Perry MD, Xiang Q, Zhang F, Zhang J, Bailey P, Erkek S, Hoadley KA, Hou Y, Huska MR, Kilpinen H, Korbel JO, Marin MG, Markowski J, Nandi T, Pan-Hammarstr\u00f6m Q, Pedamallu CS, Siebert R, Stark SG, Su H, Tan P, Waszak SM, Yung C, Zhu S, Awadalla P, Creighton CJ, Meyerson M, Ouellette BFF, Wu K, Yang H; PCAWG Transcriptome Working Group; Brazma A, Brooks AN, G\u00f6ke J, R\u00e4tsch G, Schwarz RF, Stegle O, Zhang Z; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O<\/strong>] (2020<\/strong>) Genomic basis for RNA alterations in cancer. Nature<\/u><\/em><\/strong> 578:129-136. doi: 10.1038\/s41586-020-1970-0<\/p>\n

        184\u00a0\u00a0\u00a0\u00a0 <\/strong>Alexandrov LB, Kim J, Haradhvala NJ, Huang MN, Tian Ng AW, Wu Y, Boot A, Covington KR, Gordenin DA, Bergstrom EN, Islam SMA, Lopez-Bigas N, Klimczak LJ, McPherson JR, Morganella S, Sabarinathan R, Wheeler DA, Mustonen V; PCAWG Mutational Signatures Working Group; Getz G, Rozen SG, Stratton MR; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O<\/strong>] (2020<\/strong>) The repertoire of mutational signatures in human cancer. Nature<\/u><\/em><\/strong> 578:94-101. doi: 10.1038\/s41586-020-1943-3<\/p>\n

        185\u00a0\u00a0\u00a0\u00a0 <\/strong>Rheinbay E, Nielsen MM, Abascal F, \u2026 ; PCAWG Drivers and Functional Interpretation Working Group; PCAWG Structural Variation Working Group; Weischenfeldt J, Beroukhim R, Martincorena I, Pedersen JS, Getz G; PCAWG Consortium\u00a0 [Including Zaikova O, Bjerkehagen B, Myklebost O<\/strong>] (2020<\/strong>) Analyses of non-coding somatic drivers in 2,658 cancer whole genomes. Nature<\/u><\/em><\/strong> 578:102-111. doi: 10.1038\/s41586-020-1965-x<\/p>\n

        186\u00a0\u00a0\u00a0\u00a0 <\/strong>Gerstung M, Jolly C, Leshchiner I, Dentro SC, Gonzalez S, Rosebrock D, Mitchell TJ, Rubanova Y, Anur P, Yu K, Tarabichi M, Deshwar A, Wintersinger J, Kleinheinz K, V\u00e1zquez-Garc\u00eda I, Haase K, Jerman L, Sengupta S, Macintyre G, Malikic S, Donmez N, Livitz DG, Cmero M, Demeulemeester J, Schumacher S, Fan Y, Yao X, Lee J, Schlesner M, Boutros PC, Bowtell DD, Zhu H, Getz G, Imielinski M, Beroukhim R, Sahinalp SC, Ji Y, Peifer M, Markowetz F, Mustonen V, Yuan K, Wang W, Morris QD; PCAWG Evolution & Heterogeneity Working Group; Spellman PT, Wedge DC, Van Loo P; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O<\/strong>] (2020<\/strong>) The evolutionary history of 2,658 cancers. Nature<\/u><\/em><\/strong>578:122-128. doi: 10.1038\/s41586-019-1907-7<\/p>\n

        187\u00a0\u00a0\u00a0\u00a0 <\/strong>Li Y, Roberts ND, Wala JA, Shapira O, Schumacher SE, Kumar K, Khurana E, Waszak S, Korbel JO, Haber JE, Imielinski M; PCAWG Structural Variation Working Group; Weischenfeldt J, Beroukhim R, Campbell PJ; PCAWG Consortium [Including Zaikova O, Bjerkehagen B, Myklebost O<\/strong>] (2020<\/strong>) Patterns of somatic structural variation in human cancer genomes. Nature<\/u><\/em><\/strong> 578:112-121. doi: 10.1038\/s41586-019-1913-9<\/p>\n

        188\u00a0\u00a0\u00a0\u00a0 Georgiesh T<\/strong>, Naml\u00f8s HM<\/strong>, Sharma N, Lorenz S, Myklebost O<\/strong>, Bjerkehagen B, Meza-Zepeda LA,<\/strong>Boye K (2021<\/strong>) Clinical and molecular implications of NAB2-STAT6 fusion variants in solitary fibrous tumor. Pathology<\/strong> doi: 10.1016\/j.pathol.2020.11.010<\/p>\n

        189\u00a0\u00a0\u00a0\u00a0 Stabell M<\/strong>, S\u00e6ther T, R\u00f8hr \u00c5K, Gabrielsen OS, Myklebost O<\/strong> (2021<\/strong>) Methylation-dependent SUMOylation of the architectural transcription factor HMGA2. Biochemical and Biophysical Research Communications<\/strong>, doi: 10.1016\/j.bbrc.2021.02.099<\/p>\n

        190\u00a0\u00a0\u00a0\u00a0 Grad I, Hanes R<\/strong>, Ayuda-Dur\u00e1n P, Kuijjer ML, Enserink JM, Meza-Zepeda LA, Myklebost O<\/strong> (2021<\/strong>) Discovery of novel candidates for anti-liposarcoma therapies by medium-scale high-throughput drug screening. PLoS One<\/strong> doi: 10.1371\/journal.pone.0248140<\/p>\n

        191<\/strong>\u00a0\u00a0\u00a0\u00a0 Peneder P, St\u00fctz AM, Surdez D, Krumbholz M, Semper S, Chi-card M, Sheffield NC, Pierron G, Lapouble E, T\u00f6tzl M, Erg\u00fcner B, Barre-ca D, Rendeiro AF, Agaimy A, Boztug H, Engstler G, Dworzak M, Bernkopf M, Taschner-Mandl S, Ambros IM, Myklebost<\/strong> O<\/strong>, Marec-Berard P, Burchill SA, Brennan B, Strauss SJ, Whelan J, Schleiermacher G, Dirksen U, Hutter C, Boye K, Ambros PF, Delattre O, Metzler M, Bock C, Tomazou E (2021<\/strong>) Accurate detection and classification of Ewing sarcoma tumors based on cell-free DNA fragmentation patterns inferred from whole genome sequencing. Nature Communications<\/u><\/em><\/strong>DOI:10.1038\/s41467-021-23445-w<\/p>\n

        192\u00a0\u00a0\u00a0\u00a0 <\/strong>Nakken S, Saveliev V, Hofmann O, M\u00f8ller P, Myklebost O<\/strong>, Hovig E (2021<\/strong>) Cancer Predisposition Sequencing Reporter (CPSR): a flexible variant report engine for high-throughput germline screening in cancer. Internat J Cancer<\/strong> doi: 10.1002\/ijc.33749<\/p>\n

        193\u00a0\u00a0\u00a0\u00a0 <\/strong>Sveen A, Johannessen B, Eilertsen IA, R\u00f8sok BI, Gulla M, Eide PW, Bruun J, Kryeziu K, Meza-Zepeda LA, Myklebost O<\/strong>, Bj\u00f8rnbeth BA, Skotheim RI, Nesbakken A, Lothe RA (2021<\/strong>) The expressed mutational landscape of microsatellite stable colorectal cancers. Genome Medicine <\/u><\/em><\/strong>13:142. doi: 10.1186\/s13073-021-00955-2.<\/p>\n

        194\u00a0\u00a0\u00a0\u00a0 Naml\u00f8s H, Sk\u00e5rn M<\/strong>, Ahmed D, Grad I<\/strong>, Andresen K, Kresse S<\/strong>, Serra M, Scotlandi K, Llombart-Bosch A, Myklebost O<\/strong>, Lind G, Meza-Zepeda LA<\/strong> (2022<\/strong>) miR-486 expression is regulated by DNA methylation in osteosarcoma BMC Genomics<\/strong> 23:142. doi: 10.1186\/s12864-022-08346-6<\/p>\n

        195\u00a0\u00a0\u00a0\u00a0 <\/strong>Misund K, Hofste op Bruinink D, Coward E, Hoogenboezem RM, Rustad EH, Sanders MA, Rye M, Sponaas AM, van der Holt B, Zweegman S, Hovig E, Meza-Zepeda LA<\/strong>, Sundan A, Myklebost O<\/strong>, Sonneveld P, Waage A. (2022<\/strong>) Clonal evolution after treatment pressure in multiple myeloma: heterogenous genomic aberrations and transcriptomic convergence Leukemia<\/u><\/em><\/strong> DOI: 10.1038\/s41375-022-01597-y JIF 12,9<\/p>\n

        196<\/strong>\u00a0\u00a0\u00a0\u00a0 Venizelos A, Engebrethsen C, Deng W, Geisler J, Geisler S, Iversen GT, Aas T, Aase HS, Seyedzadeh M, Steinskog ES, Myklebost O<\/strong>, Nakken S, Vodak D, Hovig E, Meza-Zepeda LA<\/strong>, L\u00f8nning PE, Knappskog S, Eikesdal HP (2022<\/strong>) Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel\u00a0 monotherapy Genome Med<\/u><\/em><\/strong> doi: 10.1186\/s13073-022-01090-2 JIF 15,3<\/p>\n

        197<\/strong>\u00a0\u00a0\u00a0\u00a0 Ballinger ML, Pattnaik S, Mundra PA, Zaheed M, Rath E, Priestley P, Baber J, Ray-Coquard I, Isambert N, Causeret S, van der Graaf WTA, Puri A, Duffaud F, Le Cesne A, Seddon B, Chandrasekar C, Schiffman JD, Brohl AS, James PA, Kurtz JE, Penel N, Myklebost O<\/strong>, Meza-Zepeda LA<\/strong>, Pickett H, Kansara M, Waddell N, Kondrashova O, Pearson JV, Barbour JV, Li S, Nguyen TL, Green MJ, Kaplan W, Ravishankar S, Copty J, Powell JE, Ahn JH, Kim JU, Randall RL, Tucker K, Judson I, Sarin R, Haber M, Marshall G, Cairns MJ, Blay JY, Thomas DM (2023<\/strong>) Heritable defects in telomere and mitotic function selectively predispose to sarcomas Science<\/u><\/em><\/strong> doi: 10.1126\/science.abj4784 JIF 63,8<\/p>\n

        198\u00a0\u00a0\u00a0\u00a0 Zhou Y, Zhu J, Stein F, Rettel M, Perez-Perri JI, Roth EK, Myklebost O, Meza-Zepeda LA<\/strong>, von Deimling A, Fu C, Brosig AN, Boye K<\/strong>, Nathrath M, Blattmann C, Lehner B, Hentze MW, Kulozik AE (2023<\/strong>) Systematic analyses of RNA-binding proteins uncover therapeutically promising vulnerabilities in osteosarcoma. Nat Commun<\/em><\/strong> under revision<\/em><\/p>\n

        199\u00a0\u00a0\u00a0\u00a0 Anzar I, Malone B, Samarakoon P, Vardaxis I, Simovski B, Fontenelle H, L Meza-Zepeda LA<\/strong>, Stratford R, Keung EZ, Burgess M, Tawbi HA, Myklebost O<\/strong>, and Clancy T (2023<\/strong>) The interplay between neoantigens and immune cells in sarcomas treated with checkpoint inhibition. Front. Immunol.<\/strong> In press<\/em><\/p>\n

        200\u00a0\u00a0\u00a0\u00a0 Naml\u00f8s HM<\/strong>, Khelik K, Nakken S, Vod\u00e1k D, Hovig E, Myklebost O<\/strong>, Boye K, Meza-Zepeda LA<\/strong> (2023<\/strong>) Chromosomal instability and a deregulated cell cycle are intrinsic features of high-risk gastrointestinal stromal tumours with a metastatic potential. Molecular Oncology<\/strong> In press<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

        Naml\u00f8s H, Kresse SH, M\u00fcller CR, Henriksen J, S\u00e6ter G, Bruland \u00d8, Holdhus R, Bjerkehagen B, Steen VM , Myklebost O (2012) Global gene expression profiling of human osteosarcomas reveals metastasis-associated chemokine pattern Sarcoma 2012, 1\u201312. doi:10.1155\/2012\/639038 Thomas DM, Wilhelm M, Cleton-Jansen AM, Dirksen U, Entz-Werl\u00e9 N, Gelderblom H, Hassan B, J\u00fcrgens H, Koster J, … Continue reading Myklebost Lab Publications 2012-23<\/span><\/a><\/p>\n","protected":false},"author":3681,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"footnotes":""},"class_list":["post-77","page","type-page","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/presonc.w.uib.no\/en\/wp-json\/wp\/v2\/pages\/77","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/presonc.w.uib.no\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/presonc.w.uib.no\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/presonc.w.uib.no\/en\/wp-json\/wp\/v2\/users\/3681"}],"replies":[{"embeddable":true,"href":"https:\/\/presonc.w.uib.no\/en\/wp-json\/wp\/v2\/comments?post=77"}],"version-history":[{"count":2,"href":"https:\/\/presonc.w.uib.no\/en\/wp-json\/wp\/v2\/pages\/77\/revisions"}],"predecessor-version":[{"id":86,"href":"https:\/\/presonc.w.uib.no\/en\/wp-json\/wp\/v2\/pages\/77\/revisions\/86"}],"wp:attachment":[{"href":"https:\/\/presonc.w.uib.no\/en\/wp-json\/wp\/v2\/media?parent=77"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}